Inventor
SCHENK DALE B
US70 patents
⚠️ This page may combine multiple inventors who share the name “SCHENK DALE B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NEURALAB LTD
26 patentsUS7014855B2Mar 21, 2006
Prevention and treatment of amyloidogenic disease
NEURALAB LTD122 citations99
US6982084B2Jan 3, 2006
Prevention and treatment of amyloidogenic disease
NEURALAB LTD85 citations99
US6972127B2Dec 6, 2005
Prevention and treatment of amyloidogenic disease
NEURALAB LTD120 citations99
US6946135B2Sep 20, 2005
Prevention and treatment of amyloidogenic disease
NEURALAB LTD74 citations99
US6913745B1Jul 5, 2005
Passive immunization of Alzheimer's disease
NEURALAB LTD142 citations99
US6905686B1Jun 14, 2005
Active immunization for treatment of alzheimer's disease
NEURALAB LTD120 citations99
US6890535B1May 10, 2005
Pharmaceutical compositions and methods for treatment of amyloid diseases
NEURALAB LTD130 citations99
US6875434B1Apr 5, 2005
Methods of treatment of Alzheimer's disease
NEURALAB LTD191 citations99
US6866850B2Mar 15, 2005
Prevention and treatment of amyloidogenic disease
NEURALAB LTD145 citations99
US6866849B2Mar 15, 2005
Prevention and treatment of amyloidogenic disease
NEURALAB LTD155 citations99
US6787139B1Sep 7, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD114 citations99
US6787138B1Sep 7, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD113 citations99
US6787144B1Sep 7, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD116 citations99
US6787143B1Sep 7, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD96 citations99
US6787140B1Sep 7, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD111 citations99
US6787523B1Sep 7, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD154 citations99
US6787637B1Sep 7, 2004
N-Terminal amyloid-β antibodies
NEURALAB LTD202 citations99
US6743427B1Jun 1, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD281 citations99
US6710226B1Mar 23, 2004
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
NEURALAB LTD163 citations99
US6923964B1Aug 2, 2005
Active immunization of AScr for prion disorders
NEURALAB LTD75 citations98
US6750324B1Jun 15, 2004
Humanized and chimeric N-terminal amyloid beta-antibodies
NEURALAB LTD202 citations98
US6962707B2Nov 8, 2005
Prevention and treatment of amyloidogenic disease
NEURALAB LTD64 citations97
US6818218B2Nov 16, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD58 citations97
US6761888B1Jul 13, 2004
Passive immunization treatment of Alzheimer's disease
NEURALAB LTD228 citations97
US6808712B2Oct 26, 2004
Prevention and treatment of amyloidogenic disease
NEURALAB LTD53 citations96
US6936246B1Aug 30, 2005
Passive immunization of ASCR for prion disorders
NEURALAB LTD18 citations93
ELAN PHARM INC
8 patentsUS6114133ASep 5, 2000
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
ELAN PHARM INC187 citations98
US6284221B1Sep 4, 2001
Method for identifying β-amyloid peptide production inhibitors
ELAN PHARM INC132 citations97
US7928203B2Apr 19, 2011
Chimeric, humanized, or human antibody 2A4
ELAN PHARM INC38 citations96
US6018024AJan 25, 2000
Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
ELAN PHARM INC69 citations96
US7977316B2Jul 12, 2011
Prevention and treatment of amyloidogenic diseases
ELAN PHARM INC19 citations93
US7427392B1Sep 23, 2008
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
ELAN PHARM INC22 citations92
US7186881B2Mar 6, 2007
Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence
ELAN PHARM INC23 citations91
US6287793B1Sep 11, 2001
Diagnostic methods for alzheimer's disease
ELAN PHARM INC62 citations91
JANSSEN ALZHEIMER IMMUNOTHERAP
6 patentsUS8034339B2Oct 11, 2011
Prevention and treatment of amyloidogenic disease
JANSSEN ALZHEIMER IMMUNOTHERAP33 citations96
US7964192B1Jun 21, 2011
Prevention and treatment of amyloidgenic disease
JANSSEN ALZHEIMER IMMUNOTHERAP37 citations93
US7893214B2Feb 22, 2011
Humanized antibodies that recognize beta amyloid peptide
JANSSEN ALZHEIMER IMMUNOTHERAP41 citations93
US7790856B2Sep 7, 2010
Humanized antibodies that recognize beta amyloid peptide
JANSSEN ALZHEIMER IMMUNOTHERAP26 citations93
US7727957B2Jun 1, 2010
Treatment and delay of outset of Parkinson's disease
JANSSEN ALZHEIMER IMMUNOTHERAP44 citations92
US7700751B2Apr 20, 2010
Humanized antibodies that recognize β-amyloid peptide
JANSSEN ALZHEIMER IMMUNOTHERAP38 citations92
ATHENA NEUROSCIENCES INC
5 patentsUS5721130AFeb 24, 1998
Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of βAPP
ATHENA NEUROSCIENCES INC244 citations99
US5605811AFeb 25, 1997
Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
ATHENA NEUROSCIENCES INC180 citations99
US5441870AAug 15, 1995
Methods for monitoring cellular processing of β-amyloid precursor protein
ATHENA NEUROSCIENCES INC316 citations99
US5604102AFeb 18, 1997
Methods of screening for β-amyloid peptide production inhibitors
ATHENA NEUROSCIENCES INC165 citations98
US5837672ANov 17, 1998
Methods and compositions for the detection of soluble β-amyloid peptide
ATHENA NEUROSCIENCES INC185 citations97
ELAN PHARMA INT LTD
2 patentsATHENA NEUROSCIENCES
1 patentCALIFORNIA BIOTECHNOLOGY INC
1 patentSCHENK DALE B
1 patentShowing the top 50 of 70 patents by PatentIndex Score.